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INTRODUCTION 
Osteosarcoma is the most common primary malignant bone tumor with an 
incidence of 400 cases/year (US) and 5 year survival rate of 63%.Bimodal age 
distribution is seen in Osteosarcoma with >60% presenting in the first 2 decades of life 
and about 10% in >60years. The mean age of presentation in males is 18 years compared 
to 17 years in females. Males: Females ratio is 1.6:1 
1, 2
. The exact cause of 
osteosarcoma is unknown, even though rapid bone growth during puberty, 
environmental factors and genetic predisposition has been implicated; the vast majority 
apparently arises spontaneously. 
Osteosarcoma arises from the metaphysis of long bones most cases. Most common site 
of osteosarcoma is around the knee joint; distal femoral in 44% and proximal tibia in 
17%. Third common site is proximal humerus. Other rarer sites are axial skeleton and 
craniofacial bones
1
. Clinical features are pain, limp and swelling. Diagnosis is from 
clinical history, radiographic evidence and histological examination. Bone scan and 
CT/MRI help in assessing the extent of the tumour. 
Accurate diagnosis of osteosarcoma is from: 
– Clinical history 
– Radiographic evidence 
– Histological examination 
• Extention of local involvement is known from: 
– Bone scan 
– CT 
– MRI  
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Clinical features of Osteosarcoma are: 
• Sudden onset of symptoms 
• Pain 
• Swelling - Fusiform eccentric configuration. 
• Painful mass appears near end of long bone.  
– Skin over it is stretched,  
– Shiny with dilated veins and  
– Increased local temperature,  
– Consistency soft to firm/hard.  
– Restriction of joint movements,  
– Limp,  
– Pathologically fracture  
 
Classification of osteosarcoma: 
• Primary/idiopathic 
– Conventional 
– Telangiectatic 
– Small cell 
– Fibrohistiocytic 
– Low-grade intramedullary 
– Multicentric 
• Secondary 
– Pagets disease 
– Radiation associated with benign preexisting conditions 
– Radiation induced 
– Assocaited conditions 
Juxtacortical 
• Parosteal 
• Periosteal 
• High-grade surface 
• Dediffrentiated parosteal  
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Histological features of osteosarcoma are: 
• Absolute criteria for diagnosis of this lesion are sarcomatous stroma and direct formation 
of tumour osteoid and bone by the malignant connective tissue 
• Fibroblastic (fibrosarcomatous) 
• Chondroblastic (chondrosarcomatous) 
• Osteoblastic 
• Telangiectatic 
• Small cell variety  
 
Before 1970, the only mode of treatment was amputation with a survival rate of 
15-20%. Adjuvant chemotherapy was started in 1970 and neoadjuvant chemotherapy 
was started in the late 70s. With chemotherapy and surgery, the 5 year survival for non-
metastatic extremity osteosarcoma is currently 65-75 %.
3
 Current approach is to treat 
patients with neoadjuvant chemotherapy to treat micrometastatic disease and to facilitate 
limb sparing surgery. Various combinations of cisplatin, doxorubicin, high dose 
methotrexate and ifosfamide are currently used 
4
. 
Neo-adjuvant chemotherapy offers the unique opportunity to evaluate the 
response to chemotherapy histologically on the resected specimen. Most investigators 
have agreed that > 90% tumour necrosis is considered good response to pre-op 
chemotherapy in Osteosarcoma.
5- 11
 The degree of histological response of the primary 
tumour was closely related to the risk of systemic metastatic recurrence 
7, 12
 Response to 
pre-op chemotherapy was confirmed as the most important prognostic factor in 
osteosarcoma
13
. Post-operative treatment modifications in poor responders have failed to 
show significant change in outcome. 
9
 
The goal of surgical treatment is to safely remove the tumour yet preserve as 
much extremity function as possible. Depending on the anatomical location of the 
10 
 
tumour this can be achieved by ablative techniques such as amputation, disarticulation 
or by limb salvage procedures. 
14, 15
 
Quality of life in osteosarcoma survivors have assessed using various scoring 
systems such as MSTS( musculoskeletal tumour society), Toronto Extremity Salvage 
Scale (TESS) scores, Functional Mobility Assessment (FMA).
16
 Traditionally, 
physicians have believed that limb-salvage surgery has functional and cosmetic 
advantages over amputation, yet the literature is equivocal.  Robert et al performed a 
study on 57 adolescents treated for extremity osteosarcoma, (33 limb salvage and 24 
amputation) on various aspects of quality of life, body image, self-esteem, and social 
support and found that participants with more functional lower limbs had better quality 
of life than did those with less functional lower limbs regardless of whether they 
underwent amputation or limb-salvage surgery 
17
. 
This study is undertaken to look at clinical profile of children with osteosarcoma, 
treatment refusal and abandonment of treatment in this group.  In our unit, children are 
treated on either a two drug (Cisplatin + Doxorubicin) or a three drug (Cisplatin + 
Doxorubicin + high dose methotrexate) protocol, based on the financial status. We will 
compare the outcome of children treated on these two protocols in terms of age at 
presentation, localized or metastatic disease, response to pre-op chemotherapy and 
overall survival. We will also look at treatment refusal and abandonment in this study 
population. We have devised a simple scoring system assessing functional ability of our 
patients in their day-to-day life. This has been pretested in 6 patients for ease of 
administration for direct interview or telephone interview.  We will compare the quality 
11 
 
of life of survivors who had limb salvage vs amputation surgery using this scoring 
system. 
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EPIDEMIOLOGY 
Osteosarcoma is the 8
th
 commonest malignant tumour of childhood representing about 
2.4% of all malignancies in this age group
1
 and is the most common malignant bone 
tumor seen in both children and adolescents (19% of all bone tumours)
18
. Overall 
incidence is about 5 per million in children less than 19 years
18
. Osteosarcoma has a 
bimodal age distribution with the first peak seen during the adolescent growth spurt
19
.  
The second peak occurs after 60 years of age.  
The incidence of osteosarcoma is higher in males than in females, occurring at a rate of 
5.4 per million persons per year in males vs. 4.0 per million in females 
18
. 
ETIOLOGY  
The exact etiology of osteosarcoma is still unknown however; epidemiologic, 
environmental and genetic factors have been studied. 
Incidence of osteosarcoma is the highest during the adolescent growth spurt suggesting a 
close relationship
18
. Ottaviani suggests that rapidly proliferating cells may be more 
susceptible to oncogenic agents and mitotic errors
18
. 
The environmental factor that is definitely known to predispose to osteosarcoma is 
exposure to radiation
18
. Exposure to alkylating agents may also be associated with 
osteosarcoma
18
. 
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Several genetic factors have been found to predispose to osteosarcoma. Hereditary 
retinoblastoma which is associated with RB1 gene
18
 and Li-Fraumeni syndrome is 
associated with p53 gene
20
.  
CLINICAL PRESENTATION 
Osteosarcoma is a highly aggressive tumor which usually involves the long bones and 
often metastasizes to the lungs
18
. Tumors are thought to originate from the metaphysis of 
long bones in most cases and are primary mesenchymal tumors that are characterized 
histologically by the production of osteoid by malignant cells
18
.  
Most common site of osteosarcoma is around the knee joint; distal femoral in 44% and 
proximal tibia in 17%. Third common site is proximal humerus. Other rarer sites are axial 
skeleton and craniofacial bones 
1.18,19,21
.  
Symptoms include pain, swelling and a limp with duration of symptoms ranging from 1-
3months 
1,20,22
.
 
60-80% of the children have localized disease at presentation and around 20-40% of them 
have metastatic disease
18,22,23
.  
 
 
HISTOLOGY 
Osteosarcoma is defined by the presence of malignant mesenchymal cells which produce 
osteoid.   High-grade osteosarcoma,is the most frequent subtype and accounts for 80–
15 
 
90% of all osteosarcomas. Other subtypes are osteoblastic, chondroblastic, and 
fibroblastic. Other high-grade types are telangiectasic, small cell osteosarcoma, and high 
grade surface osteosarcoma. Low-grade central osteosarcoma and paraosteal 
osteosarcoma are low-grade malignancies, while periosteal osteosarcoma is an 
intermediate-grade
22
. 
TREATMENT 
Before 1970, the most common mode of treatment was amputation. Despite good local 
control, most patients developed metastasis within a short time and succumbed to their 
disease. The 2 year overall survival was 15-20% and 5 year disease free survival rate was 
12%
18
.  
Adjuvant chemotherapy was started in 1970
1
 with dramatic improvement in outcome. 
Doxorubicin and methotrexate were among the first drugs to be used successfully
18
. 
Cisplatin and ifosphamide were subsequently added.  The goal of adjuvant chemotherapy 
was to eradicate the micro metastasis which is present at the time of diagnosis. It was 
found that combination of different chemotherapeutic agents yielded better results as 
compared to single drug regimes. This improved the disease free survival upto 70%
1
. 
Neo-adjuvant chemotherapy was started in the late 70s
1
. This was used to treat micro 
metastatic disease and to facilitate limb sparing surgery
18,19
. Neo-adjuvant chemotherapy 
offers the unique opportunity to evaluate the response to chemotherapy histologically on 
the resected specimen. Most investigators have agreed that > 90% tumour necrosis is 
considered good response to pre-op chemotherapy in Osteosarcoma
1,18,19,21
. The degree of 
histological response of the primary tumor was closely related to the risk of systemic 
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metastatic recurrence
6,18
 . Response to pre-op chemotherapy was confirmed as the most 
important prognostic factor in osteosarcoma
18
. Post-operative treatment modifications in 
poor responders have failed to show significant change in outcome
18
.  
With chemotherapy and surgery, the 5 year survival for non-metastatic extremity 
osteosarcoma is currently 65-75 %
1
.  
CHEMOTHERAPEUTIC AGENTS AND REGIMENS USED IN 
OSTEOSARCOMA 
At present, high dose methotrexate, doxorubicin, cisplatin and ifosfamide are considered 
the most efficacious in osteosarcoma and are used in various combinations.  
Methotrexate is an antifolate drug which blocks the action of dihydrofolatereductase. It 
was one of the first drugs found to be efficacious in osteosarcoma
18,19
. High dose 
methotrexate requires good supportive care including hydration, alkalization of urine and 
folinic acid rescue. Inspite of this some patients will experience severe toxicity. The 
development of acute renal failure is the potentially life threatening complication. 
Methotrexate is primarily cleared by the kidney and renal dysfunction will delay the 
clearance, increasing the other toxic effects of the drug
18
. 
Doxorubicin is an anthracycline which was first used in osteosarcoma in early 1070s
18
. 
This drug continues to be included in current treatment regimes. Anthracycline therapy 
can be associated with both early and late cardiotoxicity. Severe cardiomyopathy has 
been reported during long term follow up of children who have been treated with 
doxorubicin.
18 
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Cisplatin was also found to be efficacious in the treatment of osteosarcomas
18
 and is 
used in multiagent regimens in the treatment of osteosarcoma. Cisplatin therapy requires 
supportive care with hyperhydration and the major toxic effects include ototoxicity and 
nephrotoxicity.  
Ifosphamide has proven activity against osteosarcoma and has been included in many 
chemotherapy regimens.
18
 Supportive measures decrease the incidence of 
haemorrhagicuropathy. Ifosfamide is also associated with significant CNS toxicity. 
The above 4 agents are currently used in various combinations however; the best 
combination is still under debate.  
Bramwell et al
24
 from European osteosarcoma intergroup, compared doxorubicin(DOX) 
and cisplatin(CDDP) with doxorubicin, cisplatin and the additional high dose 
methotrexate(HD MTX) and found that disease free survival(DFS) was 57% vs 41% for 
CDDP/DOX as compared to  CDDP/DOX/HD MTX. The overall survival was 64% Vs 
50% which was not significant. They concluded that the results with CDDP/DOX were 
comparable to CDDP/DOX/HD MTX. Souhami et al also found 44% event free survival 
(EFS) with CDDP/DOX
25
. 
Addition of high dose methotrexate of 8-12gm/m2 to the above regimen has shown to 
improve 5 year event free survival by another 10-15%
26
.  
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Table 1: Results of selected osteosarcoma protocols for localized extremity 
osteosarcoma. 
 
S.No Protocol  
 
Patients Preoperative 
chemotherapy 
Response  Postoperative 
chemothearpy 
Event-
free 
References  
1 COSS-80 116 MTX-HD, 
DOX,DDP 
Any  MTX-HD, 
DOX,DDP 
68% at 
2.5 y 
Winkler 
1984  
2 COSS-82 59 MTX-HD, 
DOX,DDP 
Good  MTX-HD, 
DOX,DDP 
68% at 
5 y 
Winkler 
1988  
3 SSG T-10 97 MTX-HD Good MTX-HD, 
BCD 
54% at 
5 y 
SAETER 
1991  
4 EOI-80831 99 DOX,DDP Any  57% at 
5y 
Bramwell 
1992  
99 MTX-HD, 
DOX,DDP 
Any  41% at 
5 y 
Bramwell 
1992  
5 EOI-80861 199 DOX,DDP Any DOX,DDP 44% at 
5 y 
Souhami 
1997(49) 
6 IOR/OS-2 164 MTX-HD, 
DOX,DDP 
Good MTX-HD, 
DOX,DDP 
59% at 
10y 
Bacci 2000  
Poor MTX-HD, 
DOX,DDP, 
IFOS,ETO 
7 EOI-8629-
4690 
250 DOX,DDP Any DOX,DDP 41% at 
3y 
Lewis 
2003   
254 DOX,DDP+ 
G-CSF 
Any DOX,DDP+ 
G-CSF 
46% at 
3Y 
8 SSG-VIII 113 MTX-HD, 
DOX,DDP 
Good MTX-HD, 
DOX,DDP 
63% at 
5Y 
Smeland 
2003  
9 INT 0133 172 MTX-HD, 
DOX,DDP 
Any MTX-HD, 
DOX,DDP 
71% at 
3y 
Meyers 
2005  
In a meta analysis of 19 studies where neoadjuvant chemotherapy was given ,the mean 5-
year event free survival  (EFS) was 48% for 2- drug regimens and 58% for 3 drug 
regimens, with a 5- year overall survival (OAS) of 62% and 70%, respectively. This 
analysis further showed that 4 drug regimens including methotrexate plus adriamycin 
plus cisplatin plus ifosfamide (MAP(Ifo)) had significant better outcome (EFS: 
HR=0.701 (95% confidence interval [95% CI]: 0.615-0.799); OAS: HR=0.792 (95% CI: 
0.677-0.926) than 2-drug regimens, but there was no significant difference between MAP 
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and MAPIfo or plus etoposide
4
.Currently Combination of cisplatin, doxorubicin and high 
dose methotrexate, given pre and postoperatively, is considered standard treatment for 
localized high grade osteosarcoma. 
 
LIMB SALVAGE SURGERY 
Before chemotherapy was used, osteosarcomas were treated with ablative surgery alone. 
This had a poor outcome as majority of patients developed metastasis and the five-year 
overall survival (OS) was less than 20%
27
.  
Chemotherapy alone does not even come close to controlling the primary tumor.  Surgery 
therefore, cannot be avoided if cure is to be achieved.  
The most important risk factor for local failure is inadequate surgical margins. With the 
introduction of neo-adjuvant chemotherapy, surgery became easier as the pre treated 
tumors were better demarcated against the surrounding tissues
28
 this allowed more limb 
salvage procedures.  
A good tumor response also contributes to the safety of surgery. Several groups have 
found local failure rates which were lower for good as opposed to poor responders to 
preoperative chemotherapy. 
29
 
Response and margins interact, and the local failure rate becomes excessive if inadequate 
margins and poor response come together. Limb-salvage surgery may be associated with 
20 
 
increased local failure rates in poor responders, implying that margins are sometimes not 
as wide as assumed during surgery
30, 31
.  
The goal of surgical treatment is, therefore, to safely remove the tumour yet preserve as 
much extremity function as possible. Over the past 3 decades surgical techniques have 
improved and led to newer types of reconstructive surgeries with use of prosthesis and in 
the past two decades, there has been a major shift away from amputations towards limb 
salvage surgery.  
QUALITY OF LIFE AMONG SURVIVIORS (COMPARING LIMB SALVAGE 
vs AMPUTATION) 
Improvement in the chemotherapeutic regimes and availability of reliable reconstruction 
options in the treatment of osteosarcoma has resulted in improved mortality and 
morbidity. This makes quality of life after treatment completion an important 
consideration. 
WHO defines Quality of Life as “individuals’perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns”. This definition highlights the multiple 
components that contribute to “quality of life” which according to Nagarajan31 , would 
include physical functioning, disease/treatment related symptoms, psychological 
functioning and social functioning. 
Literature on quality of life in survivors of osteosarcoma is varied in terms of aims and 
assessment tools. Various scoring systems such as MSTS( musculoskeletal tumour 
21 
 
society), Toronto Extremity Salvage Scale (TESS) scores, Functional Mobility 
Assessment (FMA) have been used.
16
 Traditionally, physicians have believed that limb-
salvage surgery has functional and cosmetic advantages over amputation, yet the 
literature is equivocal. Robert et al performed a study on 57 adolescents treated for 
extremity osteosarcoma, (33 limb salvage and 24 amputation) on various aspects of 
quality of life, body image, self-esteem, and social support and found that participants 
with more functional lower limbs had better quality of life than did those with less 
functional lower limbs regardless of whether they underwent amputation or limb-salvage 
surgery 
32
. 
Studies done by Mathew R et al
2
, Rougraff et al
3
 and Renard et al
4
 reported that 
functional outcome and patient satisfaction appear to be at least as good, and probably 
better after skeletal reconstruction than after amputation. They also reported that limb 
sparing surgery is associated with additional surgical procedures and complications 
which are three times more common than amputation group. In another study Otis et al
5
 
reported that prosthetic reconstruction provides superior function whereas, the patients 
studied by Harris et al
6
 functioned similarly.  
Other studies have also shown that although limb salvage surgery seems to have better 
outcome in terms of function
789
, there was a higher rate of complications 89 and there 
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was no significant difference in the two groups when patients’ perception of quality of 
life was compared. 
10
 
No studies were found to compare these two groups in the Indian scenario. 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
 
23 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
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i) To study the clinical profile of children with osteosarcoma. 
 
ii) Outcome of children treated for osteosarcoma on two chemotherapy protocols 
 
iii) To look at treatment refusal and abandonment in the study population 
 
iv) To compare the quality of life in children with osteosarcoma who had amputation 
versus limb sparing surgery. 
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METHODOLOGY 
Children and adolescents upto 18 years of age with a diagnosis of osteosarcoma, who 
attended  Paediatric Hematology- Oncology division of Department of Pediatrics, 
Christian Medical College, Vellore from 2004 till March 2012 were included in this 
study. Their demographic data, symptoms and signs, investigations such as biopsy 
reports, imaging and bone scans were collected from the hospital clinical record system.  
Treatment details were obtained from the data base in the department.  The follow up 
information was also collected from the hospital clinical records. Quality of life of those 
who have completed treatment and on follow up was done using an indigenously 
prepared and pretested questionnaire.   
Diagnosis of Osteosarcoma was confirmed in all patients from the clinical history, 
radiological findings and histopathological examination. Children were then divided into 
those with high grade osteosarcoma and others. Those with high grade osteosarcoma 
were treated on one of the two treatment protocols based on their financial status. 
Children without any financial constraints received a three drug regimen (MAP) using 
Cisplatin 100mg/m2/day on day-1 + Doxorubicin 25mg/m2/day x 1-3 days + 
Methotrexate 8-12gm/m2/day on days 21 and 29.   
In those with limited finance methotrexate was omitted(CD). Response to treatment was 
assessed at surgery by percentage of tumour necrosis for those who received neoadjuvant 
chemotherapy.  Adjuvant chemotherapy was then planned based on patient affordability 
as well as response to treatment. Those children who have completed treatment were 
27 
 
followed up regularly for recurrence of disease, orthopedic intervention and 
complications of treatment as well as for quality of life.  
For the purpose of this study, the following information was collected from all children 
diagnosed to have osteosarcoma (Appendix-1): demographic data, age and sex 
distribution of patients, localized vs metastatic disease at diagnosis, joints involved at 
presentation, histological types of osteosarcoma. Those with high grade osteosarcoma 
were divided into CD or MAP group based on the pre-operative chemotherapy received 
and further analyzed for response to treatment, type of surgery, completion of treatment, 
abandonment, relapse as well as survival.   
The study was approved by the Institution Review Board. Both the proformas – Data 
collection as well as QOL questionnaire were filled up after obtaining consent/Assent. 
Both children and parents were provided with information sheets regarding 
proforma/questionnaire. The information sheet with consent and assent forms were 
provided in English as well as local languages. 
Quality of life of the survivors was analyzed with a pretested questionnaire in 6 patients 
(3 direct and 3 by telephonic interview.) Questionnaire comprised of simple questions 
related to activities of daily living in the community. (Appendix -2) Quality of life was 
compared among survivors who had amputation versus limb sparing surgery. Children 
were also asked to rate them against their peers for day to day activities of life. This 
depicts their perception of their quality of life.  
28 
 
Statistical methods- used software SPSS 16, Basic frequency distribution, Chi 
square test, t-test and survival analysis. 
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RESULTS 
 
SECTION I : CLINICAL PROFILE OF OSTEOSARCOMA STUDY 
POPULATION 
 
Medical Records of 81 children with osteosarcoma, who were seen in Paediatric 
Hematology-Oncology outpatient clinic at Christian Medical College Vellore during the 
study period 2004 to 2012 March, were analyzed. The clinical profiles of these children 
were studied. 
Table 1: Age and sex distribution 
Age Male Female Total 
<5 years 2 (5%) 2 (5%) 4 (5%) 
6-10 years 13(30%) 10(27.5%) 23 (28 %) 
>10 years 27(65%) 27 (67.5%) 54 (67%) 
Total 42 39 81 
 
 
The age and sex distribution of the study population is shown in Table-1. The mean age 
at presentation was 11.4 years, with a range of 3 to 17 years. There were four children 
less than 5 years of age at diagnosis, their primary tumours were in the distal femur(2) , 
proximal tibia(1) and proximal humerus(1). 67% of children were adolescents at 
diagnosis.  
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Figure 1:Sex distribution 
 
Male to Female ratio in this study population was 1:1.07. 
 
 
 
Figure 2: Demographic distribution 
42
52%
39
48% Male 
Female
Sex
Total no. of Patients - 81
24
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9
5
3
2 2
1 1 West Bengal
Jharkhand
Andhra Pradesh
Tamil Nadu
Bangladesh
Kerala
Meghalaya
Assam
Orissa
Pondicherry
Karnataka
Demography
Total no. of Patients - 81
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Table 2: Geographic  distribution of patients 
 
Place Number  Percentage 
West Bengal 24 29.6% 
Jharkhand 13 16% 
Andhra Pradesh  11 13% 
Tamil Nadu 10 12.3% 
Bangladesh 9 11.1% 
Kerala 5 6.1% 
Meghalaya 3 3.7% 
Assam 2 2.4% 
Orissa 2 2.4% 
Pondicherry 1 1.2% 
Karnataka 1 1.2% 
Total 81 100% 
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Table 3: Duration of symptoms 
Duration Number Percentage 
<2 months 40 49 % 
2-4 months 22 27 % 
>4 months 19 24 % 
Total 81 100% 
 
 
 
Figure 3:Duration of symptoms 
The duration of symptoms before diagnosis was established varied from 0.25-18months 
with a mean duration of 3.31 months.75%of children presented within 4 months of onset 
of symptoms.  
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Table-4A:Presenting symptom vs duration of symptoms  
Presenting symptom <2 months 2-4months >4months Total 
Pain & Swelling 27 11 11 49 
Pain & swelling with fever 3 3 2 8 
Swelling alone 5 4 0 9 
Pain alone 1 1 2 4 
Path. fracture with swelling 1 0 2 3 
Path. Fracture with pain & swelling 3 1 1 5 
Pain, swelling &fungating ulcer 0 1 0 1 
Weakness of lower limbs 0 0 1 1 
Weakness of lower limbs with pain 0 0 1 1 
Total 40 21 20 81 
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Table 4B: Age at diagnosis vs duration of symptoms 
Age group </=2months 2-4months >4months Total 
</=10years 15 8 4 27 
> 10years 25 14 15 54 
Total 40 22 19 81 
 
 
 
 
 
 
 
 
The above tables show duration of symptoms vs presenting symptom  and age at 
diagnosis in our patients. Pain and swelling of the limb was the most common symptom. 
It was interesting to note that 10%of children had pathological fracture at presentation; all 
of them were >10years of age, nine had localized disease and five of them had biopsies 
done elsewhere prior to coming to CMC.  Two children had vertebral disease and 
presented with weakness of lower limbs and another child presented with a fungating 
ulcer in the arm.  There was no significant difference between presenting symptom and 
duration or age at diagnosis in this group 
. 
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Figure 4: Site of primary tumour 
 
 
 
 
 
The most common site of the tumour was in the distal femur 52% (42/81) followed by 
17.2% (14/81) each in proximal tibia and proximal humerus. 75% (61/81) of the children 
had thetumour around the knee joint. 
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Table 5: Biopsy report 
Biopsy report Number 
High grade 71 
Intermediate Grade 3 
Low grade  7 
Total 81 
 
 
 
Figure 5: Biopsy report 
Diagnosis of osteosarcoma was established based on histopathological examination. The 
tumour was divided into high, intermediate or low grade based on standard criteria. 71/81 
children had high grade osteosarcoma.17/81 children had biopsies done elsewhere and 
diagnosis was made before coming to CMC; these biopsies were reviewed here and 
diagnosis of osteosarcoma was confirmed.     
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Table 6: Detailed Biopsy report 
Biopsy report Number 
High grade  
           Osteosarcoma (CAN WE CLUB THIS WITH THE HIGH GRADE?) 7 
           High grade spindle cell osteosarcoma 3 
           High grade osteosarcoma with telangiectatic change 1 
          Poorly differentiated osteosarcoma 2 
           High grade osteosarcoma 58 
Intermediate Grade  
          Intermediate grade osteosarcoma 3 
Low grade   
          Low grade spindle cell osteosarcoma 1 
          Low grade osteosarcoma 3 
          Low grade chondroblasatic osteosarcoma 2 
          Chondroblastic osteosarcoma 1 
Total 81 
Majority of children had high grade disease. 
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Table 7: Stage of disease at diagnosis.  
Disease Number Percentage  
Localized 67 83% 
Metastatic 14 17% 
Total 81 100% 
 
 
 
Figure 6: Stage of disease at diagnosis 
Based on radio-imaging and nuclear scan, the tumour was divided into localized or 
metastatic disease at diagnosis. 83% of children in this group had localized disease at 
diagnosis.  
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Table 8: Site of tumourVs metastatic disease 
 
Site Localized  Metastatic  Total Number 
Distal femur 33 8 41 
Proximal humerus 6 3 9 
Proximal tibia 13 2 15 
Thoracic vertebra 1 1 2 
Proximal fibula 5 0 5 
Distal tibia 3 1 4 
Proximal femur 2 0 1 
Proximal radius 1 0 1 
Distal ulna 1 0 1 
Mid shaft femur 1 0 1 
Iliac bone 1 0 1 
Total 67 14 81 
 
 
Knee joint was the most common site of tumour in localized disease as well as in those 
who presented with metastatic disease. Sites of metastasis were bone (8), lungs (5) and 
both(1).There was no significant difference in duration of symptoms between localized or 
metastatic disease.  
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Table 9: Treatment options chosen by those completed treatment 
Treatment options at diagnosis Number 
Opted for treatment 77 
Opted against treatment nil 
Transferred to another centre 2 
Palliative treatment 2 
 
 
Figure 7: Treatment options 
After establishing the diagnosis, various treatment options were discussed with the family 
based on the type of tumour, extend of the primary leasion, localised vs. metastatic 
disease. None of our patients opted against some form of treatment.  
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Table 10:Outcome of all the cases included in this study at the time of analysis 
Completed treatment , in first CR (alive & disease free) 30 
Completed treatment, in second CR ( relapsed, alive and disease free) 5 
Completed treatment , relpased and died 10 
Completed treatmet, died of other causes 1 
Completed treatment, lost to follow up  3 
Sent home on Palliation 2 
Transferred to other centres 2 
Abandoned treatment 16 
Died  while on treatment 3 
On treatment 9 
Total 81 
CR- complete remission 
48/72 (66%)children completed treatment. Excluding the 9 children who are currently on 
treatment, the overall survival in our group is 35/72 (48%) and event free survival is 
30/72(41%). The abandonment rate was 22% (16/72(22%).  
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Table 11: Details of 12 patients who are not included in the analysis. With their Age, 
site, biopsy, localized/metastatic, treatment received and outcome. 
 Age Site Biopsy Localised
/Metasta
tic 
disease 
Rx.received Outcome 
1 13 Distal 
femur 
High grade 
OS 
Localised Outside  3cycles (details 
not known), here CDx3, 
Surgery(LSS), MAPx8, 
Recurrence, Surgery 
(Amputation) 
Lost to follow 
up 
2 13 Distal 
femur 
Osteosarco
ma 
Localised Outside 6cycles of 
cyclophosphamide, 
cisplatin & etoposide, 
Surgery (LSS), IFOS+ETO x 
2. 
Lost to follow 
up after that 
3 10 Proximal 
humerus 
Possible 
osteosarco
ma 
Localised Outside one course of 
vincristine, 
cyclophosphamide & 
doxorubicin, here MAPx2, 
Surgery (LSS), MAPx4 
Alive and 
disease free 
4 15 Distal 
femur 
Poorly 
differentiat
ed 
osteosarco
ma 
Localised Outside 2cycles of chemo 
(details not known), here 
Surgery (amputation), 
IFOS+ETO x 4 
Lost follow 
up after that 
5 6 Proximal 
tibia 
High grade 
OS with 
telangiecta
tic changes 
Localised Amputation, MAP x 6 Alive and 
disease free 
6 10 Distal 
tibia 
High grade 
OS 
Metastati
c 
Surgery  (amputation), 
CDx2 
Refused 
treatment, 
came back 
with 
extensive 
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mets and 
died 
7 13 Distal 
tibia 
High grade 
OS 
Localised Surgery (amputation), 
CDx5. 
Lost to follow 
up after that 
8 10 Distal 
ulna 
High grade 
telangiecta
tic OS 
Localised Surgery (amputation), 
CDx6,MAPx1, 
Relapsed 
with pulm. 
Mets, 
Surgery 
(thoracotomy 
excision), 
IFOS+ETO x3. 
Now alive an 
d well 
9 6 Distal 
femur 
High grade 
OS 
Localised Surgery (amputation) 
done, went back to local 
hospital (transferred) for 
continuation  further 
chemotherapy.  
Lost to follow 
up after that 
10 15 T4 
vertebra 
Low grade 
OS 
Localised  CD was planned to take in 
local hospital (transferred) 
and come for further 
assessment, Lost to follow 
up with us, but seen in 
PMR where he had spine 
decompression.  
Lost to follow 
up with us 
but is alive 
with 
paraplegia 
11 14 Distal 
femur 
High grade 
OS 
Metastati
c 
Refused treatment, 
wanted palliation so sent 
home on oral etoposide 
Lost to follow 
up after that 
12 14 Distal 
femur 
High grade 
OS 
Metastati
c 
Refused treatment, 
wanted palliation so sent 
home on oral morphine 
and paracetamol 
Lost to follow 
up after that 
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SECTION II:  
OUTCOME OF PATIENTS TREATED ON 2 DIFFERENT PRE-OP 
CHEOTHERAPY PROTOCOLS -CISPLATIN AND DOXORUBICIN(CD) Vs CISPLATIN, 
DOXORUBICIN AND METHOTREXATE(MAP) 
In this section we plan to compare two chemotherapy protocols used in our unit for 
children with  high grade osteo sarcoma.51 children with high grade osteosarcmawho 
were treated on one or the other protocols (CD or MAP)  were included in further 
analysis. Those who are currently on treatment was also excluded.   
Table 12:  Treatment Groups 
Group Chemo. Drugs Number 
1 MAP 30 
2 CD 21 
Total  51 
 
 
 
Figure 8:Treatment groups 
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Figure 9: Sex distribution in each groups 
 
 
 
 
 
 
 
 
 
Figure 10: Age distribution among the groups 
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Figure 11:Duration of symptoms in each group 
 
 
 
 
 
 
Figure 12:Duration of symptoms Vs.Sex 
 
 
 
 
In almost half of them symptoms present within 2 months duration 
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Figure 13:Duration of symptoms Vs. Age groups 
 
 
 
  
 
Figure 14: Site of tumour Vs. Groups 
 
 
 
 
Distal femur is the most common tumour site 
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Figure 15: Site of tumour Vs.Sex 
 
 
 
 
 
Figure 16: Site of tumour Vs. Age groups 
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Table 13: Response to pre-op chemotherapy 
 CD MAP 
Good response (>90% necrosis) 6 (40%) 12 (50%) 
Poor response (<90% necrosis) 9 (60%) 12 (50%) 
Total Available 15 24 
  
 
Figure 17: Response to Pre-op chemotherapy 
The response to pre-op chemotherapy was assessed based on percentage necrosis seen on 
biopsy at the time of excision of tumour. 15/21 in CD group and 24/30 had tumour 
necrosis documented in the biopsy report. More than 90% necrosis was considered good 
response. 50% in the MAP group and 40% in CD group had good response to pre-op 
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chemotherapy.  There is no statistically significant difference between the two groups. 
(p=0.54) 
Table 14: SURGERY 
 CD MAP 
Amputation 12 10 
Limb salvage 6 18 
Total 18 28 
 
 
Figure 18: Surgery 
In CD group 2 children abandoned treatment before surgery and 1 died during while on 
treatment, hence only 18 underwent surgery. Similarly in MAP group 2 children 
abandoned treatment before surgery and only 28 underwent surgery. 66% of children in 
CD group had amputation compared to 35% in MAP group. This difference was 
statistically significant (p=0.04). The cost of limb salvage surgery was much higher than 
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that of amputation hence many of those belonged to poorer socio-economic strata opted 
for amputation.  
 
 
 
 
 
Table no.15: Type of amputation 
Type of Amputation Number Percentage 
Above knee amputation 12 50% 
Hip disarticulation 
6 25% 
Forequarter amp. 
2 8% 
Above elbow amp. 
2 8% 
Below knee amp. 
1 4% 
Shoulder disarticulation 
1 4% 
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Total 24 100% 
 
Among those who has had amputation, 12 of them 50% under went above knee 
amputation, reason being some of them with extracompartmental disease definitely 
needed amputation and the other reason is because of financial constraints who would 
have benefitted with limb sparing surgery. Lack of finance most of them went for 
amputation 
 
TREATMENT COMPLETION: 
 
Table 16: Treatment completion 
 
 CD MAP 
Completed treatment 12 23 
Abandoned 8 3 
Died during  treatment 1 4 
Total 21 30 
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Figure 19: Treatment completion 
At the time of analysis 23/30 in the MAP group and 12/21 in the CD group have 
completed treatment. In the CD group 3children abandoned treatment before surgery and 
5 after surgery and in MAP group 2 abandoned treatment before surgery and 1 after 
surgeryAbandonment rate was higher in the CD group 38%, compared to 10% in the 
MAP group. This was probably because children from low socio-economic strata 
received CD. One each from both groups died of sepsis while on treatment and 3 in MAP 
group died of progressive disease.  
OUTCOME OF THOSE COMPLETED TREATMENT 
Table 17:Outcome at the time of analysis 
 
 CD (12) MAP (23) 
Alive  and well 9 16 
Lost to follow up 1 2 
Died 2 5  
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Table 20: Outcome at the time of analysis 
Mean follow up in the CD group was 19 months (1-59 months) and in the MAP group 
was 28 months (2-72months).Two childrenin the CD group and 5 in the MAP group 
relapsed. All those who relapsed, but one in the MAP group, died of disease. One child in 
the MAP group died 6 weeks after completion of treatment due to an unrelated illness.   
In CD group 9/2 are alive and disease free,  compared to 16/23 in the MAP group at the 
time of this analysis. 
Table 18:Outcome vs tumour response 
 CD-Alive  CD-Relapsed MAP- Alive  MAP relapsed  
>90% 4/6 2/6 9/12 3/12 
<90% 8/9 1/9 9/12 3/12 
 
 
9
1
2
16
2
5
0
5
10
15
20
Alive and  well Lost to follow up Died
Out come at the time of analysis
CD-12
MAP-23
56 
 
 
Figure 21: Outcome Vs Tumour response 
 
Among those with tumour necrosis recorded in their biopsy reports, overall 18 children 
had good response to pre-op chemotherapy and 21 had poor response. 13/18 with good 
response and 17/21 with poor response are alive and well. There was no significant 
difference between these two groups or the type of pre-op chemotherapy they received. 
Table 19:Outcome of CD group those who have completed treatment: 
S.n
o 
Se
x 
Diseas
e 
Neoad.
Rx 
Surgery Adj.
Rx 
Necro
sis 
Relapse Adverse 
events 
Stat
us  
1 F Locali
sed 
CDx3 Amputat
ion 
IEx6 <90%    Aliv
e  
2 F Locali
sed  
CDx3 LSS IEx4 <90%  SNHL Aliv
e 
3 F Locali
sed  
CDx2 Amputat
ion 
CDx
4 
>90%  Stump 
overgrowth,re
vised 
Aliv
e 
4 M Locali
sed 
CDx2 Amputat
ion 
CDx
4 
>95% Relapse
d (Pulm 
Mets)I
Ex6 
SNHL Died 
5 F Locali CDx4 LSS IEx4 <90%   Aliv
0
1
2
3
4
5
6
7
8
9
CD alive CD relapsed MAP alive MAP relapsed
4
2
9
3
8
1
9
3
Outcome Vs. Tumour response
>90%
<90%
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sed e 
6 F Locali
sed 
CDx2 Amputat
ion 
CDx
4 
>90%   Aba
nd 
(A) 
7 F Locali
sed 
CDx2 Amputat
ion 
CDx
4 
>90%   Aliv
e 
8 M Locali
sed 
CDx3 LSS MAP
x3 
<90%  Cracked 
prosthesis, 
revised 
Aliv
e 
9 M Locali
sed 
CDx2 LSS CDx
4 
>90%   Aliv
e 
10 M Locali
sed 
CDx2 Amputat
ion 
CDx
3 
<90%   Died 
11 M Locali
sed 
CDx2 Amputat
ion 
CDx
4 
>90%  SNHL Aliv
e 
12 F Locali
sed 
CDx2 Amputat
ion 
CDx
4 
<90%   Aliv
e 
13 F Locali
sed 
CDx3 Amputat
ion 
IEx6 <90%   Aliv
e  
14 F Locali
sed  
CDx3 LSS IEx4 <90%  SNHL Aliv
e 
15 M Locali
sed 
CDx2 LSS CDx
4 
<90%   Aliv
e 
 
 
 
 
 
 
 
 
Table 20:Outcome of MAP group those who have completed treatment: 
S.n
o 
Se
x 
Disease Neoad.
Rx 
Surgery Adj.R
x 
Necro
sis 
Relapse Ad.even
ts 
Stat
us 
1 F Metasta
tic 
MAPx
2 
LSS MAP
x4 
>90%   Aliv
e 
2 F Localis
ed 
MAPx
1 
Amputat
ion 
CDx4 <90%  SNHL Aliv
e 
3 F Localis
ed 
MAPx
3 
LSS IEx4 <90%  Dislocat
ed 
prosthesi
s, 
revised 
Aliv
e 
4 M Localis
ed 
MAPx
2 
LSS MAP
x4 
<90% Relapsed(P
ath. 
fracture) 
 Aliv
e 
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IEx2 
5 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%  Non 
union 
graft, 
revised 
Aliv
e 
6 M Localis
ed 
MAPx
2 
Amputat
ion 
MAP
x4 
<90% Relapsed 
(Bone 
mets) 
 Died 
7 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90% Relapsed 
(H’gic 
Pl.effusion
) MAP 
 Died 
8 M Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%  SNHL, 
Non 
union 
graft, 
revised 
Aliv
e 
9 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90% Relapsed, 
(IE) 
AKAmp, 
Sent on 
palliation 
 Died 
10 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%  SNHL, 
Prosthes
is 
lengthen
ing done 
Aliv
e 
11 M Locasli
ed 
MAPx
2 
LSS MAP
x4 
<90%   Aliv
e 
12 F Localis
ed 
MAPx
3 
LSS IEx5 <90%   Aba
nd 
13 M Metasta
tic 
MAPx
3 
LSS IEx4 <90% Relapsed 
(Pulm.mets
) Sent on 
palliation 
 Aliv
e 
14 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%  Liver 
failure 
after 1 
month 
of 
completi
on of Rx 
Died 
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15 M Metasta
tic 
MAPx
2 
Amputat
ion 
MAP
x4 
<90% Ralapsed, 
Pulm.mets(
IE) 
 Died 
16 M Localis
ed 
MAPx
2 
Amputat
ion 
MAP
x4 
>90%   Aliv
e 
17 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%   Aliv
e 
18 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%   Aliv
e 
19 M Localis
ed 
MAPx
3 
LSS IEx3 <90%   Aliv
e 
20 M Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%   Aliv
e 
21 M Metasta
tic 
MAPx
2 
Amputat
ion 
MAP
x4 
<90%   Aliv
e 
22 F Localis
ed 
MAPx
2 
LSS MAP
x4 
>90%   Aliv
e 
23 M Localis
ed 
MAPx
2 
Amputat
ion 
MAP
x4 
<90%   Aliv
e 
24 F Localis
ed 
MAPx
2 
LSS MAP
x4 
<90   Aliv
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21 : Among those who had fractures: 
S.n
o 
Age at 
presenta
tion 
Duration 
of 
symptoms 
Site of 
tumour 
Disease   Biopsy 
done 
Opte
d for 
Rx. 
Rx. 
Grou
p 
Outcome 
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1 13 years 1 month  Dist.Femur Localised  Outsid
e 
Yes CD Lost 
follow up 
2 11 years 0.25mont
h 
Dist.Femur Localised Outsid
e 
Yes MAP Alive 
3 14 years 3 months Prox.Humer
us 
Metastat
ic 
Outsid
e 
Yes MAP Abandon
ed 
4 14 years 1 month Dist.Femur Localised Here Yes CD Abandon
ed 
5 10 years 6 months Dist.Femur Localised Outsid
e 
Yes CD Alive 
6 11 years 12 months Prox.Humer
us 
Localised Here Yes CD Abandon
ed 
7 12 years 0.5 month Dist.Femur Localised Here Yes CD Alive 
8 15 years 6 months Dist.Femur Localised Outsid
e 
Yes IFOS 
+ETO 
Alive 
 
III: QUALITY OF LIFE: 
For quality of assessment, all those who have completed treatment and alive were 
contacted; 33/35children responded. The mean duration of follow up in the responders 
was 3 years with a range of 6 months to 8 years. The scoring system was devised based 
on day to day activities of life such as eating, dressing, bathing, ambulation as well as 
their social life.  
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Table22 A: QOL score 
Score Number of children 
0-7 0 
8-13 0 
14-20 6 
21-27 27 
Total 33 
 
 
Table 22 B: QOL score 
: 
Score (marks out of 27) Number 
15 1 
17 1 
18 1 
19 2 
20 1 
21 3 
22 5 
23 5 
24 7 
25 2 
26 3 
27 2 
 
The mean score was 21.5 with a range of 15-27. 
 
Table 23: QOL score vs. site of tumour: 
Site of tumour Score 1-7 Score 8-13 Score 14-
20 
Score 21-
27 
Total 
Lower limb 0 0 4 23 27 
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Upper limb 0 0 0 4 4 
Axial skeleton 0 0 2 0 2 
Total 0 0 6 27 33 
 
 
 
Figure 22: QOL score Vs site of tumour 
 
 
 
Table 24: Type of surgery vs. QOL 
Surgery  Score 1-7 Score 8-13 Score 14-20 Score 21-27 Total 
LSS 0 0 0 16 16 
Amputation 0 0 4 10 14 
Total 0 0 4 26 31 
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Figure 23:QOL Vs Type of surgery 
 
 
Table 25: Age at diagnosis Vs. QOL 
Age Score 1-7 Score 8-13 Score 14-20 Score 21-27 Total 
<10years   2 9 11 
>10 years   4 18 22 
Total   6 27 33 
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Figure 24: QOL Vs Age a diagnosis 
In tables 22-25 we assessed quality of life score in those completed treatment. 6/33(18%) 
scored 14-20 and the rest 21-27. While looking at the site of tumour, both children with 
axial skeleton tumour scored 14-20 compared to other sites. When we compared the type 
of surgery and QOL, all those who had limb salvage surgery rated themselves to be 
having a good quality of life.  
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Table 26: Patients’ perception of their QOL compared to peers  
Score Number 
Upto 25% 3 
26-50% 6 
51-75% 22 
76-100% 2 
Total 33 
 
 
Figure 25:Patients perception, compared to peers 
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Table 27 Patients perception of QOL vs QOL score 
Score 0-25% 26-50% 51-75% 76-100% 
Patients perception 3 6 22 2 
Actual score 0 0 6 27 
 
Figure 26: Patients perception of QOL vs. QOL score. 
 
It was interesting to note that even though while using the scoring system, all patients 
scored >50%, while their perception of abilities compared to peers seemed much less. 
3/33 rated them to have only up to25% of ability compared to their peers, 6/33 with 26-
50%. In the QOL scoring27/33 rated themselves to be more than 75%, in their perception 
majority (22/33) rated themselves between 51-75%. However this difference was not 
statistically significant. (p>0.05) 
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DISCUSSION 
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DISCUSSION 
CLINICAL PROFILE  
In this descriptive study we first looked at the clinical profile of all children with 
osteosarcoma registered in our unit from 2004. A total of 81 children were recruited for 
the study. The male: female ratio is 1.025, which is similar to a study from Ethiopia
34
. 
Other studies from around the world showed a slightly male preponderance
1
 with males 
being affected with osteosarcoma 1.5 to 3 times more than the female population. 
The age at presentation ranged from 3-17 years with an average of 11.5years.This was 
similar to other reports
5
,
6
.  52 (72%) were  more than 10 years old  at presentation and  23 
(28%) were aged less than or equal to 10 years. Among the less than 10 year group, a 
small number (5%) were less than 5 years old at diagnosis.  
The geographic profile of our patients showed that children travel long distances to attend 
a specialized centre for treatment.72/81 were from India and 9/81 were from Bangladesh. 
62% of children belonged to various states of eastern part of our country such as West 
Bengal, Jharkhand, Meghalaya, Assam & Orissa. Similar geographic distribution is seen 
among all children attending our unit with various other malignancies also. This directly 
depicts dearth of specialists and centres with adequate facility in our country. Travelling 
long distances to fetch treatment increases the indirect cost of treatment such as boarding, 
lodging as well as loss of job for parents. This may also contribute to abandonment of 
treatment, and poor survival in children with cancer.   
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The duration of symptoms varied from 0.25-12months with a mean duration of 
2.7 months. It was less than 2months in almost half (49%) of the patients, 2-4months in 
27%  and more than 4months in 24% of the patients. In a study done by Yang JY et al
35 
from Hong Kong reported the  median duration of initial symptoms as 30 (range, 0-360) 
days. Wu Set al
11
from China reported that the mean duration of symptoms as 4weeks 
with a range of 1-14weeks. 
The most common presenting symptom was swelling followed by pain.  66% (54/81) of 
them presented with both swelling and pain. About 10 % of our children had pathological 
fracture at diagnosis.  Similar presenting symptoms were reported by other authors also; 
in a study done by Staals EL  et al
22
  the  most common symptoms were swelling and 
pain 92% and 67% of the cases respectively. Yang JYet al
35
 from Hong Kong reported 
the swelling (76%) and pain (90%) were the most common presenting complaints. 
The most common site of tumour was found to be the distal end of femur 52% (42/81), 
followed by proximal end of tibia in 17% (14/81) and then proximal end of humerus in 
11% (9/81). Knee jointtumours accounted for 74% in our population. Several other 
authors also reported similar distribution of tumours. Muthupheiet al
23
 in African 
population, Yang JY, et  al
35
 from HongKong, Rech
,  
et al
36
 from Brazil  as well as 
Ottaviani G et  al
18
 reported similar sites of occurrence of osteosarcoma like our group.  
The diagnosis of osteosarcoma was confirmed by biopsy. Of the 81 patients 21% of them 
(17/81) had biopsy done outside and the rest 79% of them (64/81) are new cases and had 
biopsy done in our hospital. Of all 81 patients, 71had high grade osteosarcoma, 3had  
intermediate grade  7 of them with low grade osteosarcoma. 
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At presentation 83% (67/81) of the children with osteosarcoma had localized disease 
where as 17% (14/81) had metastatic disease.Among those with metastatic disease 5 had 
metastasis in lungs, 8 had metastasis to other bones and 1 has disease in both lungs and 
bone. Among those patients with metastastic disease 42% (6/14) of them had duration of 
symptoms <2months. Among those patients with metastatic disease 77.7% (7/9) 
belonged to MAP protocol whereas 22.8% (2/9) belonged to Cisplatin +Doxorubicin 
group (Table 16). In a study done by Yang JYet al
35
 from Hong Kong reported 76% had 
localized disease and 24% of patients had metastatic disease at presentation. In an another 
study done by RechA
,
et al
36
 from Brazil reported 38% of the patients had metastatic 
disease at presentation and 62% had localized disease. Bacci G et al
15
 from their study 
reported 83% (891/1071) had localized disease at presentation whereas 17% (180/1071) 
had metastatic disease. 
Excluding the 9 children who were on treatment at the time of analysis, 48/72 
(66%)children completed treatment.The overall survival in our group is 35/72 (48%) and 
event free survival is 30/72(41%). The abandonment rate was  16/72(22%).  
COMPARISON OF TWO CHEMPTHERAPY PROTOCOLS 
We compared two pre-operative chemotherapy protocols currently used in our centre for 
high grade osteosarcoma for  toxicity and efficacy. In each group, one child each died of 
septicemia while on treatment. Since by default poorer children received Cispatin+ 
Doxorubicin, abandonment of treatment was higher in this group comapred to MAP 
group. 
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Of those who underwent surgery, 55% (37/67) of them underwent Limb sparing 
surgery and 45% (30/67) of them underwent amputation.94% with localized disease 
underwent limb sparing surgery whereas only 6% with metastatic disease had LSS. 66% 
of children in CD group had amputation compared to 35% in MAP group. This difference 
was statistically significant (p=0.04). The cost of limb salvage surgery was much higher 
than that of amputation hence many of those belonged to poorer socio-economic strata 
opted for amputation. Rech Aet al
36
 from Brazil reported that 52% had an amputation 
and 34% received limb sparing surgery in their series. Bacci G  et al
15
 from their study 
reported that 71% of the 126 operated patients had limb salvage procedures compared to 
26%who had amputations and three patients had a rotation plasty (3%). Rhonda S  et al
32 
from their study of 57 patients participated 33(57%) who underwent limb-salvage surgery 
and 24 (43%) who underwent amputation. 
The response to pre-op chemotherapy was assessed based on percentage necrosis seen on 
biopsy at the time of excision of tumour. 15/21 in CD group and 24/30 had tumour 
necrosis documented in the biopsy report. More than 90% necrosis was considered good 
response. 50% in the MAP group and 40% in CD group had good response to pre-op 
chemotherapy.  There is no statistically significant difference between the two groups. 
(p=0.54) 
Several authors have compared good histpathological response to pre-op chemotherapy 
with survival. A response of >90% was observed in 36% of patients treated with CD and 
50% of MAP was reported by  Ian J. Lewis et al
37 
reported from their study that good 
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histologic response (>90% tumor necrosis).Provisor AJet al
10
 in their study reported that 
two hundred six patients had their tumors assessed for histologic response: 28% 
displayed a good histologic response to preoperative chemotherapy. In our series overall 
46% of 39children who had tumor necrosis  recorded had good  response. 13/18 with 
good response and 17/21 with poor response are alive and well. There was no significant 
difference between these two groups or the type of pre-op chemotherapy they received.  
At the time of analysis 23/30 in the MAP group and 12/21 in the CD group have 
completed treatment. Abandonment rate was higher in the CD group 38%, compared to 
10% in the MAP group. This was probably because children from low socio-economic 
strata received CD. Mean follow up in the CD group was 19 months (1-59 months) and in 
the MAP group was 28 months (2-72months). Two children in the CD group and 5 in the 
MAP group relapsed. All those who relapsed, but one in the MAP group, died of disease. 
One child in the MAP group died 6 weeks after completion of treatment due to an 
unrelated illness.   In CD group 9/12 are alive and disease free,  compared to 16/23 in the 
MAP group at the time of this analysis. 
In summary both CD and MAP were well tolerated, treatment related mortality was 
acceptible. Histological response to pre-op chemotherapy was similar in both groups. 
Though it seem that overall survival is better in the CD group, compared to MAP group, 
it is probably because more children were treated in MAP and they had much longer 
followup period.  
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QUALITY OF LIFE: 
It was believed that limb-salvage surgery has functional and cosmetic advantages over 
amputation, yet the literature is equivocal.Many authors reported thatThe function of 
Lower limb was a significant predictor of quality of life (p< 0.001), whereas the type of 
surgery did not impact this relationship (Robert RS et al
17
) Studies done by Mathew R et 
al
14
, Rougraff et al
38
 and Renard et al
39
 reported that functional outcome and patient 
satisfaction appear to be at least as good, and probably better after skeletal reconstruction 
than after amputation. They also reported that limb sparing surgery is associated with 
additional surgical procedures and complications which are three times more common 
than amputation group. In another study Otis et al
39
 reported that prosthetic 
reconstruction provides superior function whereas, the patients studied by Harris et al
40
 
functioned similarly.  
We analyzed quality of life using a questionnaire prepared by us, which is relevant to our 
culture and social life. It was interesting to note that while assessing ability to perform 
day-to-day activities 81% of children rated themselves as having 76-100% and 19% rated 
between 51-75%.  While looking at the site of tumour, both children with axial skeleton 
tumour scored 14-20 compared to other sites. All children with LSS rated themselves 
between 76-100% QOL. However there was no significant difference in QOL between, 
site of tumour or type of surgery  
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It was interesting to note that even though while using the scoring system, all patients 
scored >50%, their perception of abilities compared to peers seemed much less. 3/33 
rated them to have only up to 25% of ability compared to their peers, 6/33 with 26-50%. 
In the QOL scoring 27/33 rated themselves to be more than 75%, in their perception 
majority (22/33) rated themselves between 51-75%. Even though this difference was not 
statistically significant (p>0.05), this probably depicts their limitations due to altered 
body image.  
Overall, quality of life in children completed treatment for osteosarcoma seem good, both 
in their perception as well as by objective testing using a QOL questionnaire   
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SUMMARY 
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SUMMARY 
 81 children, 42 boys and 39 girls with osteosarcoma were studied.  The mean age 
at presentation was 11.4 years, with a range of 3 to 17 years. 54/81 were more 
than 10 years of age and 4 were less than 5 years of age at diagnosis.  
 Pain and swelling was the most common symptom. The common sites were distal 
end of femur followed by proximal end of tibia and proximal end of humerus. 
There was no significant difference between presenting symptom and duration or 
age at diagnosis in this group. 71/81 had high grade osteosarcoma. 67/81 children 
had localized disease at diagnosis. The incidence of pathological fracture was ---- 
 77/81 children opted for curative treatment at diagnosis. Excluding the 9 children 
who are currently on treatment,48/72 (66%)children completed treatment, of these 
30 are in 1
st
 CR and 5 in second CR. The overall survival in our group is 35/72 
(48%) and event free survival is 30/72(41%) at a mean follow up period of 3 
years with a range of 6 months to 8 years.  The abandonment rate in this group 
was 22% (16/72)   
 51 children with high grade osteosarcoma were further studied to compare the 
efficacy of two chemotherapy protocols used, namely cispatin+ Doxorubicin 
vscisplatin+ doxorubicin+ methotrexate. Children received one or the other 
protocols based on their financial status.Response to pre-op chemotherapy was 
assessed using tumout necrosis on the excised tissue; 50% in the MAP group and 
40% in CD group had good response(>90% necrosis) to pre-op chemotherapy.  
There is no statistically significant difference between the two groups. (p=0.54) 
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 66% of children in CD group had amputation compared to 35% in MAP group. 
This difference was statistically significant (p=0.04). The cost of limb salvage 
surgery was much higher than that of amputation hence many of those belonged 
to poorer socio-economic strata opted for amputation.  
 12/21 in the CD group and 23/30 in the MAP group have completed treatment. 
Abandonment rate was higher in the CD group 38%, compared to 10% in the 
MAP group. This was probably because children from low socio-economic strata 
received CD. One each from both groups died of sepsis while on treatment and 3 
in MAP group died of progressive disease.  
 
 Mean follow up in the CD group was 19 months (1-59 months) and in the MAP 
group was 28 months (2-72months). 9/10 in CD group are alive and disease free,  
compared to 10/15 in the MAP group. Longer follow up is required to comapre 
the two groups.  
 An indigenously prepared and pre-tested scoring system was used to assess 
quality of life in survivors. A score of up to 7 was considered 25%, 8-13 as 50%, 
14-20 as 75% and 21-27 as 100% QOL. 33/35 survivors responded. 6/33(18%) 
scored 14-20 and the rest 21-27. When we compared the type of surgery and 
QOL, all those who had limb salvage surgery rated themselves to be having a 
good quality of life with a score of more than 21.  
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 It was interesting to note that even though while using the scoring system, all 
patients scored >50%, while their perception of abilities compared to peers seemed 
much less. 3/33 rated them to have only up to 25% of ability compared to their 
peers, 6/33 with 26-50%. In the QOL scoring 27/33 rated themselves to be more 
than 75%, in their perception majority (22/33) rated themselves between 51-75%.  
Even though this difference was not statistically significant (p>0.05), this probably 
depicts their issues with body image. 
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LIMITATIONS 
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LIMITATIONS:  
 Sample size of children in this study was small. 
 Children were divided into treatment groups based on their financial status rather 
than by proper randomization. Rate of abandonment was higher in the CD group. 
The results of comparison between the two groups will have to be interpreted with 
caution.  
 Follow up period of those completed  ranged from 19- 28 months only. There were 
very few patients who had completed 5 years post treatment to be labeled as cancer 
survivors.  
 
 
 
 
 
 
 
 
 
81 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
82 
 
BIBLIOGRAPHY 
References: 
1.  Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and 
adolescence. N. Engl. J. Med. 1999 Jul 29;341(5):342–52.  
2.  Stiller CA, Craft AW, Corazziari I. Survival of children with bone sarcoma in 
Europe since 1978: results from the EUROCARE study. Eur. J. Cancer. 2001 
Apr;37(6):760–6.  
3.  Nelson Textbook of Paediatrics 19
th 
edition, Pages 1763-4 
4.  Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn 
PCW, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? 
Eur. J. Cancer. 2011 Nov;47(16):2431–45.  
5.  Bramwell VH, Burgers M, Sneath R, Souhami R, Van Oosterom AT, Voûte PA, 
et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable 
osteosarcoma of limbs in children and young adults: the first study of the European 
Osteosarcoma Intergroup. J. Clin. Oncol. 1992 Oct;10(10):1579–91.  
6.  Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, 
et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a 
study of the European Osteosarcoma Intergroup. Lancet. 1997 Sep 27; 350(9082):911–7.  
7.  Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, et al. 
Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial 
(COSS-82) with salvage chemotherapy based on histological tumor response. J. Clin. 
Oncol. 1988 Feb;6(2):329–37.  
8.  Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, et al. Primary 
chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the 
extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with 
intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 
1990 Jun 1;65(11):2539–53.  
9.  Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. 
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering 
experience. J. Clin. Oncol. 1992 Jan;10(1):5–15.  
10.  Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. 
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and 
83 
 
postoperative chemotherapy: a report from the Children’s Cancer Group. J. Clin. Oncol. 
1997 Jan;15(1):76–84.  
11.  Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, et al. Long-term 
results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol 
COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the 
limbs. Ann. Oncol. 1998 Aug;9(8):893–9.  
12.  Rosen G, Nirenberg A, Caparros B, Juergens H, Kosloff C, Mehta BM, et al. 
Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination 
chemotherapy (T-7). Natl Cancer Inst Monogr. 1981 Apr;(56):213–20.  
13.  Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical 
review. J. Clin. Oncol. 1994 Feb;12(2):423–31.  
14.  DiCaprio MR, Friedlaender GE. Malignant bone tumors: limb sparing versus 
amputation. J Am Acad Orthop Surg. 2003 Feb;11(1):25–37.  
15.  Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, et al. Osteosarcoma 
of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. 
J Bone Joint Surg Br. 2002 Jan;84(1):88–92.  
16.  Mahendra A, Griffin AM, Yu C et al. Correlation of MSTS-87 and TESS 
functional evaluation scores following endoprosthetic replacement for bone sarcoma. J 
Bone Joint Surg 2010; 92-B (1):64  
17.  Robert RS, Ottaviani G, Huh WW, Palla S, Jaffe N. Psychosocial and functional 
outcomes in long-term survivors of osteosarcoma: a comparison of limb-salvage surgery 
and amputation. Pediatr Blood Cancer. 2010 Jul 1;54(7):990–9.  
18.  Ottaviani G, Jaffe N et al, The epidemiology of osteosarcoma, Cancer Treat Res. 
2009:152:3-13  
19.  Hansen MF. Genetic and molecular aspects of osteosarcoma. J Musculoskelet 
Neuronal Interact. 2002 Dec;2(6):554–60.  
20.  Scholz RB, Kabisch H, Weber B, Röser K, Delling G, Winkler K. Studies of the 
RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol. 1992 
Jun;9(2):125–37.  
21.  Lee JA, Kim DH, Lim JS, Park KD, Song WS, Lee S-Y, et al. The survival of 
osteosarcoma patients 10 years old or younger is not worse than the survival of older 
patients: a retrospective analysis. Cancer Res Treat. 2007 Dec;39(4):160–4.  
84 
 
22.  Staals EL, Bacchini P, Bertoni F. High-grade surface osteosarcoma: a review of 
25 cases from the Rizzoli Institute. Cancer. 2008 Apr 1;112(7):1592–9.  
23.  Muthuphei MN, Mariba MT. Osteosarcoma in Ga-Rankuwa Hospital: a 10 year 
experience in an African population. Cent Afr J Med. 2000 Feb;46(2):41–3.  
24.  Bramwell VH, Burgers M, Sneath R, Souhami R, Van Oosterom AT, Voûte PA, 
et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable 
osteosarcoma of limbs in children and young adults: the first study of the European 
Osteosarcoma Intergroup. J. Clin. Oncol. 1992 Oct;10(10):1579–91.  
25.  Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, 
et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a 
study of the European Osteosarcoma Intergroup. Lancet. 1997 Sep 27;350(9082):911–7.  
26.  Bielack SS, Machatschek J-N, Flege S, Jürgens H. Delaying surgery with 
chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother. 2004 
Jun;5(6):1243–56.  
27.  Jongkolnee Settakorn SR. Epidemiologic study of 112 osteosarcomas in Chiang 
Mai University Hospital, Thailand. Journal of the Medical Association of Thailand = 
Chotmaihet thangphaet. 2007;90(7):1400–5.  
28.  Jaffe N, Goorin A, Link M, Watts H, Frei E, Vawter G, et al. High-dose 
methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results. 
Cancer Treat Rep. 1981;65 Suppl 1:99–106.  
29.  Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. 
Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence 
in osteosarcoma. J. Clin. Oncol. 1994 Dec;12(12):2699–705.  
30.  Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone 
osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 2006 
Oct;32(6):423–36.  
31.  Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation 
in survivors of pediatric lower-extremity bone tumors: what are the long-term 
implications? J. Clin. Oncol. 2002 Nov 15;20(22):4493–501.  
32.  Robert RS, Ottaviani G, Huh WW, Palla S, Jaffe N. Psychosocial and functional 
outcomes in long-term survivors of osteosarcoma: a comparison of limb-salvage surgery 
and amputation. Pediatr Blood Cancer. 2010 Jul 1;54(7):990–9.  
85 
 
33.  Malek F, Somerson JS, Mitchel S, Williams RP. Does limb-salvage surgery offer 
patients better quality of life and functional capacity than amputation? Clin. Orthop. 
Relat. Res. 2012 Jul;470(7):2000–6.  
34.Wamisho BL, Admasie D, Negash BE, Tinsay MW. Osteosarcoma of limb bones: a 
clinical, radiological and histopathological diagnostic agreement at Black Lion Teaching 
Hospital, Ethiopia. Malawi Med J. 2009 Jun;21(2):62–5.  
35.  Yang JYK, Cheng FWT, Wong KC, Lee V, Leung WK, Shing MMK, et al. Initial 
presentation and management of osteosarcoma, and its impact on disease outcome. Hong 
Kong Med J. 2009 Dec;15(6):434–9.  
36.  Rech A, Castro CG Jr, Mattei J, Gregianin L, Di Leone L, David A, et al. 
[Clinical features in osteosarcoma and prognostic implications]. J Pediatr (Rio J). 2004 
Feb;80(1):65–70.  
37.  Lewis I, Nooji M, Whelan J S. et al. Chemotherapy at standard or increased dose 
intensity in patients with operable osteosarcoma of the extremity: A randomised 
controlled trial conducted by the European Osteo Sarcoma Intergroup (ISRCTN 
86294690).  
38.  Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage 
compared with amputation for osteosarcoma of the distal end of the femur. A long-term 
oncological, functional, and quality-of-life study. J Bone Joint Surg Am. 1994 
May;76(5):649–56.  
 
 
 
 
 
 
 
 
86 
 
 
 
 
ANNEXURE 
 
   
  
  
  
  
  
  
  
 
 
87 
 
 
 
 
Contents: 
IRB approval form 
Participant Information sheet  
Consent form 
Assent form 
Data collection sheet- Osteosarcoma in children and adolescents 
Questionnaire- Quality of life after completion of treatment 
Originality certificate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
 
 
 
ANNEXURE 1 
89 
 
 
 
 
 
90 
 
 
91 
 
 
 
 
 
92 
 
ANNEXURE 2 
Christian Medical College, Vellore 
Participant Information sheet and Consent form 
Thesis: ‘’Clinical profile and outcome of children treated for Osteosarcoma on two 
protocols and quality of life among those who had amputation versus Limb sparing 
surgery’’ 
 
Invitation 
You are invited to participate in this study – ‘’Clinical profile and outcome of children 
treated for Osteosarcoma on two protocols and quality of life among those who had 
amputation versus Limb sparing surgery’’. The study is being conducted by Dr.David 
Suvarna Raju Parimi, PG registrar in the Department of Paediatrics, under the guidance 
of Dr.Leni Mathew (Professor and Head of the Department of Paediatric Oncology and 
Paediatrics unit-I) and Dr.Rikki John (Research Officer, Department of Paediatrics. This 
study is part of academics of The Tamil Nadu Dr.MGR Medical University, Chennai.  
We would like to take 10 minutes of your time and ask you to fill/answer this 
questionnaire. We are trying to assess the quality of life of children who have been 
treated for osteosarcoma. We would like to know if there is any change we could make in 
our treatment which would mean a better life after treatment for children who will be 
diagnosed with this problem in the future.  
We will also need your permission to look into your medical records to note the type of 
treatment you have received. Your identity will not be disclosed. Only the researchers 
named above will have access to your details and results that will be held securely at 
Christian Medical College, Vellore. Any results of this study that may be published will 
be done without any names and with care not to disclose your identity. 
Participation in this study is voluntary. Whatever you decide, it will not affect the 
treatment you receive now or in future. It will not affect your relationship with the 
hospital staff caring for you. 
If you wish to not to answer any question once you have started, you can just leave it 
empty/ say you don’t want to answer without giving any further reason. 
All it will take is 10 minutes of your time and it may benefit lots of children who like you 
will require treatment for osteosarcoma in the future, just as you benefitted from similar 
research programmes that  children with the same disease participated in before you. 
You will however have to give your consent either verbally (for telephonic interviews) or 
by signing in the consent form attached with this.  
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ANNEXURE 3 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
CONSENT FORM 
(To be used in conjunction with a participation information sheet) 
‘’Clinical profile and outcome of children treated for Osteosarcoma on two 
protocols and quality of life among those who had amputation versus Limb sparing 
surgery’’ 
1. I …………………………………………………………Son/Daughter of 
………………………………………………, agree to participate in the study 
described above by completing the said questionnaire. 
2. I agree to the researchers going through my medical records for information about 
my treatment. 
3. I agree that research data gathered from the results of the study may be published, 
provided that I cannot be identified. 
4. I understand that if I have any questions relating to my participation in this 
research, I may contact Dr David on telephone 07708077038, who will be happy 
to answer them. 
5. Complaints may be directed to the Research Office  at phone number 0416 228 
4294 
 
Signature of the participant               Name of the participant          Date 
 
 
 
Signature of participants parent       Name of participants parent   Date 
 
 
 
Signature of witness                          Name of the witness                  Date 
 
 
 
Signature of the Investigator           Name of the Investigator          Date   
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ANNEXURE 4 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
OSTEOSARCOMA IN CHILDREN-Data collection sheet 
Serial number:  
Name:  
Hospital number:  
Date of birth:  
Sex: 
Place:   
Age at diagnosis 
Presenting complaints: 1.Swelling      2.Pain     3.Fever    4.Weight loss     5.others  
Duration of symptoms:   
Co-morbid features:  
Weight:  
Height:  
Site of tumour 
Status of the patient: new case/ Biopsy done elsewhere/ partially treated 
 
Investigations  Diagnosis  Pre-op End of Rx Follow-up 
CBC     
Creatinine      
LDH     
Chest X-ray     
CT-Chest     
MRI-Limb     
Bone scan     
ECHO      
Audiogram      
Biopsy      
Diagnosis: Localised/ metastatic disease 
 
Pre-op treatment: yes/no, drugs ( CDDP/DOX vs PAM)and no of courses 
 
Surgery: 
 Limb salvage/ amputation 
Details 
Reason for choice of surgery 
Biopsy report 
% necrosis of tumour 
 
Post op Rx: drugs(CDDP/DOX, PAM, Ifos/Etop, others and courses  
 
Treatment completed: yes/no 
 If no: refused Rx/ abandoned Rx/Died while on Rx 
 If abandoned, when:  pre-op/immediate post op 
95 
 
If died while on Rx: cause of death 
 
End of treatment Assessment 
 
Follow up: duration in months  
 
Status of the patient: alive and disease free/ alive , on relapse Rx / died 
 
Cause of death: disease/ infection/ others 
 
Relpase: yes/No 
 
If yes,  when  
 site of relapse 
Rx of Relapse 
Outcome 
 
Quality of life:  
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ANNEXURE 5 
 
 
 
Quality of life after completion of treatment 
1. Are you able to eat your meals by yourself?  1) need full support,  2) some 
assistance, 3) yes 
2. Are you able to put on your dress by yourself? 1) need full support2) some 
assistance ,3)  yes,  
3. Are you able to take bath by yourself? 1)No,  2)yes with some assistance, 3) yes 
by myself 
4. Has your family made any modifications in your house after your treatment 
-To help you walk in the house – 1) yes, 2) No 
-To help you use the toilet and bath- 1) Yes, 2) No 
5. Are you able to walk? 1)No, 2) yes, with some support, 3) Yes with no support 
What kind of support do you use? ________________________________ 
If unable to walk- state reason________________________________ 
6. Are you able to climb stairs?  1) No 2)Yes  with some difficulty 3) Yes with no 
support 
If no, state reason____________________________________________ 
7. Mode of transport   
a. Before you had this disease 1)Auto rickshaw, 2)Town bus, 3) private 
car, 4)others 
b. After completion of treatment 1)Auto rickshaw, 2)Town bus, 3) private 
car, 4)others 
Any change? 1) Yes, 2) No 
Reason for change___________________________  
8. Have you been attending school /College after your treatment? 1) No, 2)Yes 
If yes, details ______________________ 
If no, why________________________________________ 
9. Do you go out with your friends? 1)No, 2)Yes 
  
10. Do you play any games/sports?  1)No, 2)Yes 
a. If yes. what games, how often__________________________________ 
11. Compared to your friends , you would  rate your ability to do the above activities 
as 
1) 25%, 2) 50%, 3)75%, 4) Same as them. 
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Quality of life of the survivors was analyzed with a pretested Questionnaire in 6 patients 
(3 direct and 3 by telephonic interview). Both the groups did not show any difference, so 
it was decided that it was acceptable to go by telephonic interview. Questionnaire 
comprised of simple questions related to activities of daily living in the community. 
Quality of life was compared among survivors who had amputation versus limb sparing 
surgery. In the initial part of the questionnaire, children were asked about the activities of 
daily living tasks (eating, dressing, bathing, walking, going to school, playing, etc). Each 
of these activities has points scored according to their capability. In the later part of the 
questionnaire children were also asked to rate them against their peers for day to day 
activities of life. This depicts their perception of their quality of life. 
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ANNEXURE 6 
 
  
          FORMAT 
 
 
 
TITLE OF THE ABSTRACT  :The clinical profile and outcome of osteosarcoma    treated on 
two protocols and quality of life among those who has had amputation versus limb sparing 
surgery. 
DEPARTMENT                                 :Paediatrics        
NAME OF THE CANDIDATE        :David Suvarna Raju Parimi 
DEGREE AND SUBJECT                :MD (Paediatrics) 
NAME OF THE GUIDE                   :Dr.Leni Grace Mathew  
 
 
OBJECTIVES: Describe the objectives of your study (maximum 30 words) 
 
To study the clinical profile of children with osteosarcoma and outcome of children treated for 
osteosarcoma on two chemotherapy protocols. To look at treatment refusal and abandonment in the study 
population. To compare the quality of life in children with osteosarcoma who had amputation versus limb 
sparing surgery. 
 
METHODS:    Explain the clinical and statistical methods used (maximum 100 words) 
 
Variables:  
outcomes: Survival based on age at diagnosis, localised vs metastatic disease, high grade vs low or 
intermediate grade tumours, extremity vs axial skeleton tumours as well as chemotherapy used in these 
patients. 
predictors: Treatment complications, deformities, 
potential confounders: Socioeconomic factors- Poorer patients received CDDP+DOX 
Data Sources/measurement: Data sources are taken from Medical records of all these patients with 
Osteosarcoma. And also from the details from Chemotherapy records. 
 
Bias: No bias. 
 
Sample size: all children with osteosarcoma registered under pediatric Hemato-Oncology will be included 
in the study. 
 
Statistical methods:  
The data will be analysed using SPSS package 16.0 version. Tests of significance to be used are Chi-square 
tests, paired sample tests and Wilcoxon signed ranked tests. 
 
 
 
 
 RESULTS:  Summarize the findings and conclusions of your study (maximum 90 words) 
 
Study included 81 children. Male: Female ratio 1.07.  Mean age at presentation was 11.4 
years. Pain with swelling was most common symptom. Most common site was distal femur. 
66% children completed treatment.  Overall survival is 48% and event free survival is  41%.  
Abandonment rate was 22%.   
50% in MAP group and 40% in CD group had good response to pre-op chemotherapy.  66% 
of children in CD group had amputation compared to 35% in MAP group. 57% in CD group 
and 76% in MAP group completed treatment. Abandonment rate was higher in CD group 38%, 
compared to 10% in MAP group.  
For quality of life 33/35 survivors responded. All those who had limb salvage surgery rated 
themselves to be having a good QOL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
